MA44780A - Préparation contenant un anticorps - Google Patents

Préparation contenant un anticorps

Info

Publication number
MA44780A
MA44780A MA044780A MA44780A MA44780A MA 44780 A MA44780 A MA 44780A MA 044780 A MA044780 A MA 044780A MA 44780 A MA44780 A MA 44780A MA 44780 A MA44780 A MA 44780A
Authority
MA
Morocco
Prior art keywords
antibody
preparation containing
preparation
Prior art date
Application number
MA044780A
Other languages
English (en)
Inventor
Tomoyuki Igawa
Chifumi Imai
Shaw Nishizawa
Atsushi Saeki
Hitoshi Sasaki
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Publication of MA44780A publication Critical patent/MA44780A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Inorganic Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
MA044780A 2016-04-28 2017-04-27 Préparation contenant un anticorps MA44780A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2016090590 2016-04-28

Publications (1)

Publication Number Publication Date
MA44780A true MA44780A (fr) 2019-03-06

Family

ID=60160798

Family Applications (1)

Application Number Title Priority Date Filing Date
MA044780A MA44780A (fr) 2016-04-28 2017-04-27 Préparation contenant un anticorps

Country Status (21)

Country Link
US (1) US20210189006A1 (fr)
EP (1) EP3449940A4 (fr)
JP (3) JP7320943B2 (fr)
KR (1) KR102456742B1 (fr)
CN (2) CN116059353A (fr)
AR (1) AR108240A1 (fr)
AU (1) AU2017255077B2 (fr)
BR (1) BR112018067792A2 (fr)
CA (1) CA3016301A1 (fr)
CL (1) CL2018003022A1 (fr)
CR (1) CR20180554A (fr)
HK (1) HK1257953A1 (fr)
IL (1) IL262589A (fr)
MA (1) MA44780A (fr)
MX (1) MX2018012648A (fr)
PE (1) PE20181889A1 (fr)
RU (1) RU2748046C2 (fr)
SG (1) SG11201807765PA (fr)
TW (2) TWI820000B (fr)
UA (1) UA126900C2 (fr)
WO (1) WO2017188356A1 (fr)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3050963B1 (fr) 2005-03-31 2019-09-18 Chugai Seiyaku Kabushiki Kaisha Procédé pour la production de polypeptide au moyen de la régulation d'un ensemble
ES2654040T3 (es) 2006-03-31 2018-02-12 Chugai Seiyaku Kabushiki Kaisha Método de modificación de anticuerpos para la purificación de anticuerpos biespecíficos
WO2007114319A1 (fr) 2006-03-31 2007-10-11 Chugai Seiyaku Kabushiki Kaisha Procédé de régulation de la cinétique sanguine d'un anticorps
CN101874042B9 (zh) 2007-09-26 2019-01-01 中外制药株式会社 利用cdr的氨基酸取代来改变抗体等电点的方法
AR080428A1 (es) 2010-01-20 2012-04-11 Chugai Pharmaceutical Co Ltd Formulaciones liquidas estabilizadas contentivas de anticuerpos
KR101398363B1 (ko) 2010-11-17 2014-05-22 추가이 세이야쿠 가부시키가이샤 혈액응고 제viii 인자의 기능을 대체하는 기능을 갖는 다중특이성 항원 결합 분자
EP3050896B1 (fr) 2013-09-27 2021-07-07 Chugai Seiyaku Kabushiki Kaisha Procédé de production d'un hétéromultimère polypeptidique
TWI701435B (zh) 2014-09-26 2020-08-11 日商中外製藥股份有限公司 測定ｆｖｉｉｉ的反應性之方法
TWI700300B (zh) 2014-09-26 2020-08-01 日商中外製藥股份有限公司 中和具有第ｖｉｉｉ凝血因子（ｆｖｉｉｉ）機能替代活性的物質之抗體
US11142587B2 (en) 2015-04-01 2021-10-12 Chugai Seiyaku Kabushiki Kaisha Method for producing polypeptide hetero-oligomer
WO2017115773A1 (fr) 2015-12-28 2017-07-06 中外製薬株式会社 Procédé pour favoriser l'efficacité de purification d'un polypeptide contenant une région fc
US11352438B2 (en) 2016-09-06 2022-06-07 Chugai Seiyaku Kabushiki Kaisha Methods of using a bispecific antibody that recognizes coagulation factor IX and/or activated coagulation factor IX and coagulation factor X and/or activated coagulation factor X
JP6496095B1 (ja) 2017-09-29 2019-04-03 中外製薬株式会社 血液凝固第ｖｉｉｉ因子（ｆｖｉｉｉ）補因子機能代替活性を有する多重特異性抗原結合分子および当該分子を有効成分として含有する薬学的製剤
FR3082427B1 (fr) 2018-06-14 2020-09-25 Lab Francais Du Fractionnement Combinaison de facteur vii et d'un anticorps bispecifique anti-facteurs ix et x
EP3849513A1 (fr) * 2018-09-11 2021-07-21 Ichnos Sciences SA Compositions comprenant un anticorps bispécifique, un tampon et un ou plusieurs agents stabilisants
CN111665352B (zh) * 2020-06-23 2024-05-17 广州市丹蓝生物科技有限公司 一种储存剂及由其制备的抗体溶液制剂及其应用
EP4272756A1 (fr) * 2021-02-05 2023-11-08 Bio-Thera Solutions, Ltd. Formulation d'anticorps anti-il-5, son procédé de préparation et son utilisation
AR127269A1 (es) * 2021-10-08 2024-01-03 Chugai Pharmaceutical Co Ltd Formulación de anticuerpo anti-hla-dq2.5
EP4442274A1 (fr) * 2021-12-01 2024-10-09 Chugai Seiyaku Kabushiki Kaisha Procédé de préparation d'une formulation contenant un anticorps
CN114544839B (zh) * 2022-01-20 2024-08-20 未名生物医药有限公司 一种抗人神经生长因子抗体的电荷变异体检测方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US6875432B2 (en) 2000-10-12 2005-04-05 Genentech, Inc. Reduced-viscosity concentrated protein formulations
WO2005035753A1 (fr) 2003-10-10 2005-04-21 Chugai Seiyaku Kabushiki Kaisha Anticorps a double specificite remplaçant une proteine fonctionnelle
ES2494921T3 (es) 2005-04-08 2014-09-16 Chugai Seiyaku Kabushiki Kaisha Anticuerpo que sustituye la función del factor VIII de coagulación sanguínea
PE20091174A1 (es) * 2007-12-27 2009-08-03 Chugai Pharmaceutical Co Ltd Formulacion liquida con contenido de alta concentracion de anticuerpo
AR080428A1 (es) * 2010-01-20 2012-04-11 Chugai Pharmaceutical Co Ltd Formulaciones liquidas estabilizadas contentivas de anticuerpos
KR101398363B1 (ko) 2010-11-17 2014-05-22 추가이 세이야쿠 가부시키가이샤 혈액응고 제viii 인자의 기능을 대체하는 기능을 갖는 다중특이성 항원 결합 분자
RU2014140137A (ru) 2012-03-08 2016-04-27 Ф.Хоффманн-Ля Рош Аг Лекарственный препарат антитела к бета-амилоиду
TW201625299A (zh) * 2014-06-20 2016-07-16 Chugai Pharmaceutical Co Ltd 用於因第ｖｉｉｉ凝血因子及／或活化的第ｖｉｉｉ凝血因子的活性降低或欠缺而發病及／或進展的疾病之預防及／或治療之醫藥組成物

Also Published As

Publication number Publication date
AU2017255077B2 (en) 2024-05-16
EP3449940A1 (fr) 2019-03-06
AR108240A1 (es) 2018-08-01
BR112018067792A2 (pt) 2019-02-12
KR20190003596A (ko) 2019-01-09
PE20181889A1 (es) 2018-12-11
TWI820000B (zh) 2023-11-01
IL262589A (en) 2018-12-31
RU2748046C2 (ru) 2021-05-19
AU2017255077A1 (en) 2018-10-04
CA3016301A1 (fr) 2017-11-02
CN108883178A (zh) 2018-11-23
CL2018003022A1 (es) 2019-01-18
US20210189006A1 (en) 2021-06-24
JP7320943B2 (ja) 2023-08-04
JP2022037069A (ja) 2022-03-08
RU2018141173A (ru) 2020-05-28
JPWO2017188356A1 (ja) 2019-03-07
UA126900C2 (uk) 2023-02-22
KR102456742B1 (ko) 2022-10-19
TW201737942A (zh) 2017-11-01
SG11201807765PA (en) 2018-10-30
JP2023145766A (ja) 2023-10-11
HK1257953A1 (zh) 2019-11-01
TW202402326A (zh) 2024-01-16
CR20180554A (es) 2019-01-10
JP7544932B2 (ja) 2024-09-03
RU2018141173A3 (fr) 2020-06-11
EP3449940A4 (fr) 2020-01-22
MX2018012648A (es) 2019-01-30
CN108883178B (zh) 2023-03-14
CN116059353A (zh) 2023-05-05
WO2017188356A1 (fr) 2017-11-02

Similar Documents

Publication Publication Date Title
MA44780A (fr) Préparation contenant un anticorps
MA47694A (fr) Anticorps anti-tigit
MA49034A (fr) Anticorps anti-lag3
MA46525A (fr) Anticorps anti-lag-3 et compositions
FR21C1030I2 (fr) Conjugué anticorps anti-her2-médicament
MA47268A (fr) Anticorps anti-gpc3
MA44659A (fr) Anticorps anti-tim-3 et compositions
MA46057A (fr) Anticorps anti-ctla4
MA44381A (fr) Format d'anticorps hétérodimères multispécifiques
MA53434A (fr) Anticorps anti-tigit
DK3606504T5 (da) Stabil antistofformulering
MA45004A (fr) Anticorps spécifiques anti-wt1-hla
MA46041A (fr) Anticorps anti-tim -3
MA50352A (fr) Anticorps multispécifiques
MA52884A (fr) Anticorps anti-il-11
MA46272A (fr) Anticorps anti-cd27
MA47472A (fr) Anticorps
MA42626A (fr) Nouveaux anticorps anti-pd-1
MA53297A (fr) Anticorps anti-icos
MA49726A (fr) Formulation d'anticorps anti-cgrp
EA201991715A1 (ru) Композиции, содержащие антитело к pdl1
MA49749A (fr) Anticorps anti-cd137
CY1124521T1 (el) Σκευασματα αντισωματος anti-cd19
MA44236A (fr) Anticorps anti-tgfbêta 2
MA44054A (fr) Plateforme d'anticorps bispécifique